Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00892736
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Conditions: Basal-Like Breast Carcinoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Breast Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Hereditary Breast and Ovarian Cancer Syndrome;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Progesterone Receptor Negative;   Prostate Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Solid Neoplasm;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib

Indicates status has not been verified in more than two years